论文部分内容阅读
1988举9月第三次全国传染病与寄生虫病学术会议上,进一步展示了流行性出血热(下称EHF或HFRS)的治疗进展,现作简述。一、特异性病因治疗: 病毒唑的应用:经过近两年临床应用病毒唑治疗EHF取得满意效果,成人0.5~0.75/日(10~15mg/kg)加入1%葡萄糖液200~500毫升内静滴,连用3日,对退热、尿蛋白消失和越期等均优于对照组。应用每次0.5,每日两次,共3日,进一步观察结果表明此药早期应用除有上述优点外,对水肿消退、血小板恢复正常时间、血浆CIC及EHF—IgG抗体水平有效降低。提示病毒唑抑制
The September 1988 Third National Conference on Infectious Diseases and Parasitology further demonstrated the progress of the treatment of epidemic hemorrhagic fever (EHF or HFRS), which is now briefly described. First, the specific cause of treatment: the application of ribavirin: after nearly two years of clinical application of ribavirin EHF achieved satisfactory results, adult 0.5 ~ 0.75 / day (10 ~ 15mg / kg) added 1% glucose solution 200 ~ 500 ml of static Dripping, once every 3 days, antipyretic, urinary protein disappear and overdue were better than the control group. The application of 0.5, twice daily, a total of 3 days, further observation showed that the early application of the drug in addition to the above advantages, edema on the ebb, platelet recovery time, plasma CIC and EHF-IgG antibody levels were effectively reduced. Tip ribavirin inhibition